The "Wolverine stack" is the street name for BPC-157 and TB-500 taken together, usually sold as one blended vial. No human trial has tested the combination. BPC-157 has animal studies and very little human data; TB-500 has animal data, and the name covers at least three different molecules. Neither is FDA-approved, a narrow July 2026 FDA advisory vote is not a rule, and both are banned in sport by WADA. Of 81 public lab results for BPC-157 plus TB-500 blends that we checked, 1 failed on fill, and every lab that measured the two peptides separately found both.
What is the Wolverine stack?
The Wolverine stack is BPC-157 and TB-500 taken together, usually sold as one pre-mixed vial. The name borrows from the Marvel character whose wounds close in seconds. It is a marketing name, not a defined formulation.
| Question | Short answer |
|---|---|
| What is in it | BPC-157 (15 amino acids) plus "TB-500", which can mean three different molecules |
| Human trials of the pair | None |
| Evidence for each peptide | Mostly rodent injury studies; very little human data |
| FDA status | Not approved. A July 2026 advisory vote is not a rule |
| Sport | Both banned at all times by WADA |
| Lab tests of blend vials | 81 public results checked; 1 failed on fill |
Sellers print the name on labels. Six Kovera certificates from five vendors carry "Wolverine" as the product name, and Janoshik tested two "Wolverine" blends for one seller in April 2026. We could not find who coined it.
US search interest grew about sixfold in a year. Google Ads data shows "wolverine stack" at 8,100 monthly searches in September 2025 and 49,500 in August 2026, the latest month available on 10 October 2026. "Wolverine peptide" went from 8,100 to 60,500 over the same months.
How did the Wolverine stack go mainstream?
Between 7 September and 9 October 2026 the term moved from forums into general news.
| Date (2026) | Source | What it said |
|---|---|---|
| 7 Sep | nference preprint, not peer-reviewed | 1,039 US patients with BPC-157 use in clinical notes; quarterly new users up 33-fold from 2020; TB-500 co-used by 12.9% |
| 15 Sep | Reuters via Medscape | "Popularly known as the 'Wolverine stack'"; 10 FAERS adverse-event reports for BPC-157 since 2021, all serious, 8 in 2026 |
| 16 Sep | Johns Hopkins Hub | Explainer for general readers |
| 24 Sep | McGill Office for Science and Society | Explainer for general readers |
| 7 Oct | The Verge, Optimizer column | BPC-157 is "one half of the infamous 'Wolverine' stack" |
| 9 Oct | Generation Iron on Jeff Nippard's ranking | BPC-157 in "low C tier", "only actually ever been studied in 30 humans, ever" |
Three caveats on that table. We have not pulled the FAERS records Reuters cited, and a FAERS report does not show the peptide caused the event. We have not checked the "30 humans" figure against the literature or watched the full video. The preprint's lead scientist told The Verge that between first use and a doctor's visit "at least two months has elapsed".
On Reddit the questions now come from first-time buyers. One October poster asks whether "they need to keep taking them even after the pain was gone?" and adds, "I don't understand how BAC water and all that stuff works" (r/Biohacking).
What do poison centers report about peptides?
The only call figure we found is local and secondhand. The Bold reported on 9 October 2026 that the Rocky Mountain Poison Control Center "received two calls related to peptides in 2024. In 2026, they received 62." The figure covers all peptides, not the Wolverine stack, and the article does not say whether 2026 means year to date. We could not confirm it, and the latest National Poison Data System report covers 2024 without a research-peptide category.
The Missouri Poison Center named the stack in a page on 11 May 2026, calling it "a combination of the BCP-157 and TB-500 peptides" (its spelling). The page says sellers' "science-backed" claims are not.
How do BPC-157 and TB-500 work?
In animal and cell studies the two act on different parts of tissue repair. That difference is the reason sellers pair them. No study has shown the effects add up in people.
| BPC-157 | TB-500 (thymosin beta-4) | |
|---|---|---|
| Origin | 15-residue sequence from a protein in human gastric juice | 43-residue protein, or fragments of it |
| Main reported action | Angiogenesis (new blood vessels), nitric oxide and VEGFR2 signalling | Binds G-actin, drives cell migration |
| Other reported effects | Growth-hormone-receptor involvement in tendon healing | Anti-inflammatory signalling; hair-follicle stem cells |
| Repair layer | Vascular and signalling | Cell migration and cytoskeleton |
| Evidence base | Mostly rodent: gut, tendon, ligament, nerve, heart | Mostly animal and cell studies |
The two are the most-cited research peptides for tissue repair and the commonest healing pair in vendor catalogs. Kovera's public certificates include 69 for BPC-157 plus TB-500 blends, against 68 for BPC-157 alone.
What do studies say about Wolverine stack doses?
No published study has tested the two peptides together at any dose. BPC-157 dose figures online are conversions from rodent studies, not results of human trials; our BPC-157 guide traces them. TB-500 figures come from vendor and forum convention, and a milligram amount means little until you know which molecule is in the vial. Pre-mixed vials fix the ratio at the factory. No study supports any ratio.
What does lab testing show for BPC-157 and TB-500?
Single-peptide and blend vials mostly match their labels. The figures below come from Kovera Labs certificates dated January to June 2026 (retrieved 2 August 2026) and 337 readable Janoshik public reports (364 indexed, collected 30 June 2026).
| Product as labelled | Lab | Records | Median purity | Lowest purity | Fill range (measured vs label) | Failed |
|---|---|---|---|---|---|---|
| BPC-157 | Kovera | 68 | 99.92% | 46.85% | 92% to 139% | 1 |
| TB-500 | Kovera | 28 | 99.93% | 99.35% | 96% to 123% | 0 |
| BPC-157 + TB-500 blend, incl. "Wolverine" | Kovera | 69 | 99.76% | 98.72% | see below | 1 |
| BPC-157 + TB-500 blend, incl. "Wolverine" | Janoshik | 12 | not reported | not reported | 89% to 120% per peptide | none flagged |
One BPC-157 vial measured 46.85% purity. Certificate KVR-2026-E91AD0, issued to Axon Peptide on 20 May 2026, shows roughly half the material was not BPC-157. The 28 TB-500 certificates, from 24 vendors, all passed.
One Kovera blend failed on fill. Certificate KVR-2026-550573, issued to Instant Peptides on 29 April 2026, measured 35.54 mg against a 40 mg label, 11.2% under, at 99.49% purity. The six "Wolverine" certificates all passed, at 98% to 116% of label.
Blend certificates do not show the split. Kovera reports one purity and one net content per vial. Four blends read about double the label (20.44 mg against "10 mg"), most likely because the label gave the amount per peptide. Janoshik measures each peptide separately but gives no purity. Across 12 Janoshik blends from 10 sellers, both peptides were present every time; the lowest value was BPC-157 at 4.46 mg against 5 mg (test 97078, January 2026).
A 99.8% blend certificate tells you the vial is mostly peptide. It does not tell you the ratio or which TB-500 is inside. Check any certificate in our COA verifier before you trust a vendor's copy. Download the data: all 81 blend results are a CSV file on our data page.
Which TB-500 is in a Wolverine blend?
Often you cannot tell from the label. "TB-500" is a research-market name that covers three molecules:
| Molecule | Size | What it is | Seen on |
|---|---|---|---|
| Thymosin beta-4 | 43 residues | The full protein | Kovera: "TB-500 (Thymosin B4)" on 23 records, "TB-500 (43aa)" on 1 |
| LKKTETQ fragment | 7 residues (17-23) | The actin-binding region of thymosin beta-4 | Kovera: "TB-500 (17-23)" on 3 records |
| Ac-SDKP | 4 residues | A peptide cut from the start of thymosin beta-4, with its own research literature | Lab identity line on two Hello Stacks "GHK-Cu + BPC-157 + TB-500" pens |
One more Kovera record says only "TB-500". The full protein and the fragments are different products, so a blend's TB-500 figure is not comparable across sellers. Our TB-500 guide has the breakdown, and our Hello Stacks review explains why we cannot yet say what those pens hold.
A commenter on an October 20-day Wolverine log wrote: "Nobody is getting true tb-500 in a wolverine blend" (r/Peptidesource). Our data does not settle that either way.
Is the Wolverine stack legal?
Neither peptide is FDA-approved, and nothing in 2026 has changed that.
| Item | Status on 10 October 2026 |
|---|---|
| FDA approval | None, for any human use |
| Advisory vote, 23 July 2026 | 8-6 with one abstention to recommend both for the 503A Bulks List (AP and law-firm counts; FDA has posted no tally). FDA's reviewers had recommended against |
| Rule or Federal Register notice | None published; compounding status unchanged |
| Temporary compounding policy | Washington Post, 7 October, citing two unnamed sources, says one is being prepared; Pink Sheet reported on 8 October that FDA drug-center staff will not recommend it. Not announced |
| Sport | WADA bans BPC-157 (S0) and "Thymosin-β4 and its derivatives e.g. TB-500" (S2) at all times |
None of this covers research-grade vials sold online, which are labelled not for human use. Earlier FDA warning letters named vendors for drug claims such as "treats injuries" on BPC-157 and TB-500 pages; see our FDA peptide enforcement timeline. Our FDA peptide vote explainer tracks each step.
What the evidence does not show
We found no published support for four common claims.
- Synergy. No study tests the pair against each peptide alone.
- "X% faster recovery". No Phase 2 or Phase 3 trial exists to produce such a figure.
- Human efficacy from the 2026 preprint. Clinicians noted improvement in 79% of the 354 users with a recorded response. Response was missing for 65.9%, half took other drugs at the same time, and there was no comparison group. The authors say the data cannot establish efficacy.
- Interchangeable doses. BPC-157 figures sit in micrograms and TB-500 figures in milligrams.
Where to go next
- Vendor audits and scores: vendors
- Single-peptide guides: BPC-157, TB-500, GHK-Cu
- The four-part blend: KLOW stack research read
- Lab data across vendors: what 1,816 Kovera COAs reveal
Sources
- Venkatakrishnan et al., "Rising Use of Unapproved BPC-157 ('Wolverine Peptide')", preprint, 7 September 2026, not peer-reviewed
- Reuters via Medscape, "Use of untested 'Wolverine' peptide ... on the rise", 15 September 2026
- The Verge, "The scariest thing about gray-market peptides is how little we know", 7 October 2026
- The Bold, "Gray-market peptides promise quick results", 9 October 2026
- Missouri Poison Center, "Is peptide stacking dangerous?", 11 May 2026
- America's Poison Centers, 2024 NPDS annual report release
- McGill Office for Science and Society, "Biohackers are reaching for Wolverine peptides", 24 September 2026
- Johns Hopkins Hub, "The compounding problem of peptides", 16 September 2026
- Jeff Nippard, "Peptides Are Insane" (YouTube) and Generation Iron write-up of his peptide ranking, 9 October 2026
- AP via PBS NewsHour, FDA advisory panel vote, 23 July 2026
- WADA Prohibited List
- Kovera Labs certificate verifier; Janoshik test 97078
- BPC-157 mechanism literature: Sikiric et al., reviews of preclinical BPC-157 research
- TB-500 / thymosin beta-4 mechanism: Goldstein and Hannappel, thymosin beta-4 reviews
- Kumar et al., 2016, Ac-SDKP
- FDA Warning Letters database
- r/Biohacking, "Wolverine stack? And peptides"; r/Peptidesource, "20 day report on Wolverine stack"
- Internal: BPC-157 peptide overview, TB-500 peptide overview, FDA peptide vote explainer, Hello Stacks review, KLOW stack research read, What 1,816 Kovera COAs reveal, Reconstitution guide, FDA peptide enforcement timeline
Frequently asked
What is the Wolverine stack?
It is BPC-157 and TB-500 used together, most often sold as one pre-mixed vial labelled "Wolverine" or "BPC-157/TB-500". The name borrows from the Marvel character who heals fast. Reuters, The Verge and McGill's Office for Science and Society all used the term in September and October 2026. It is a marketing name, not a defined formulation.
Does the Wolverine stack work?
Nobody has tested it in a controlled human trial. The evidence is rodent injury studies for each peptide alone. A 2026 preprint of 1,039 patient records found that clinicians noted improvement in 79% of the 354 users whose response was recorded, but it had no control group and its authors say it cannot show efficacy.
Is the Wolverine stack legal?
Neither peptide is FDA-approved. In July 2026 an FDA advisory committee narrowly recommended BPC-157 and TB-500 for the 503A compounding list, 8-6 by law-firm counts. That vote is advisory. As of 10 October 2026 FDA has published no rule or notice, so compounding status is unchanged. WADA bans both in sport.
Do you have to keep taking the Wolverine stack after an injury heals?
No study answers this. There are no human trials of the stack at all, so there is no data on stopping, relapse or length of use. The 2026 nference preprint found that users with a recorded duration took BPC-157 for an average of 2.2 months. That describes behaviour, not a recommended course.
Does BPC-157 cause cancer?
There is no human evidence either way. The concern is theoretical: BPC-157 promotes new blood vessel growth in animal studies, and tumours also depend on new blood vessels. No study has measured cancer risk in people taking it. FDA reviewers also said in 2026 that the substance is not well characterised.
Do Wolverine blend vials contain what the label says?
In the public records we checked, mostly yes. Kovera certified 69 BPC-157 plus TB-500 blends from February to May 2026: median purity 99.76%, one vial 11.2% under its label. Janoshik found both peptides in all 12 blends it tested. What "TB-500" means differs by seller.
Why are BPC-157 and TB-500 stacked together?
The combination targets two different repair pathways. In animal studies BPC-157 promotes angiogenesis, the formation of new blood vessels, and reduces inflammation. TB-500 binds G-actin and drives cell migration into a wound. The mechanisms don't overlap, which is the rationale for pairing them. No study has shown that pairing them adds benefit.